Skip to main content
. 2017 May 29;6(8):819–832. doi: 10.1016/j.molmet.2017.05.011

Figure 5.

Figure 5

NAD+availability and signaling in NRK2KO mice. (A) LCMS-based targeted NAD+ metabolomics to quantify NAD+ and related metabolite levels in WT and NRK2KO skeletal muscle tissue (n = 6). (B) Fold change in mRNA expression of NAD+ related signaling genes in NRK2KO skeletal muscle compared to WT (at Y axis = 1) (n = 4).